CHLOROMYCETIN (chloramphenicol sodium succinate) by Pfizer is clinical pharmacology chloramphenicol is a broad-spectrum antibiotic originally isolated from streptomyces venezuelae . Approved for surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. First approved in 1959.
Drug data last refreshed 6h ago · AI intelligence enriched 1mo ago
CHLOROMYCETIN (chloramphenicol sodium succinate) is a broad-spectrum bacteriostatic antibiotic originally isolated from Streptomyces venezuelae, approved in 1959 for injection. It treats surface ocular infections of the conjunctiva and/or cornea by inhibiting bacterial protein synthesis through interference with amino acid transfer to ribosomes. The drug exhibits minimal resistance development in staphylococci and many other bacterial species.
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely small and focused on niche indications with declining commercial support.
Clinical Pharmacology Chloramphenicol is a broad-spectrum antibiotic originally isolated from Streptomyces venezuelae . It is primarily bacteriostatic and acts by inhibition of protein synthesis by interfering with the transfer of activated amino acids from soluble RNA to ribosomes. It has been…
Worked on CHLOROMYCETIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
With zero linked job postings and a LOE-approaching lifecycle, CHLOROMYCETIN offers minimal career growth opportunity; roles are limited to legacy product management, generic transition support, and niche retained-indication teams. This product is better suited for stabilization or wind-down assignments than career acceleration roles.